Development of novel tuberculosis vaccines

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 322, Issue 11, 1999, Pages 953-958

  Hess, Jürgen ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Antigens; Carrier; DNA; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE;

CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; HUMAN; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

EID: 0033231427     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(00)87192-9     Document Type: Conference Paper

References (50)

1. The World Health Report, Making a Difference, Authors?, World Health Organization, Geneva, 1999.
2. Dooley S.W., Simone M., The extent and management of drug-resistant tuberculosis: The American experience, in: Davies P.D.O. (Ed.), Clinical Tuberculosis, Chapman & Hall, London, 1994, pp. 171-189.
3. Grange J.M., Epidemiological aspects of drug resistance, in: Mycobacteria and Human Disease, Arnold, London, 1996, pp. 124-125.
4. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P., Haddix P.L., Collins H.L., Fok A.K., Allen R.D., Gluck S.L., Heuser J., Russell D.G., Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase, Science 263 (1994) 678-681.
5. Sturgill-Koszycki S., Schaible U.E., Russell D.G., Mycobacterium-containing phagosomes are accessible to early endosomes and reflect a transitional state in normal phagosome biogenesis, EMBO J. 15 (1996) 6960-6968.
6. Clemens D.L., Horwitz, M.A., Characterization of the Mycobacterium tuberculosis phagosome and evidence that phagosomal maturation is inhibited, J. Exp. Med. 181 (1995) 257-270.
7. Deretic V., Fratti R.A., Mycobacterium tuberculosis phagosome, Mol. Microbiol. 31 (1999) 1603-1609.
8. Hmama Z., Gabathuler R., Jeffries W.A., DeJong G., Reiner N.E., Attenuation of HLA-DR expression in mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterdimers, J. Immunol. 161 (1998) 4882-4893.
9. Pancholi P., Mirza A., Bhardwaj N., Steinman R.M., Sequestration from immune CD4 T cells of mycobacteria growing in human macrophages, Science 260 (1993) 984-986.
10. Kaufmann S.H.E., Tuberculosis: The role of the immune response, The Immunologist 1 (1993) 109-114.
11. Mutis T., Cornelisse Y.E., Ottenhoff T.H., Mycobacteria induce CD4 T cells that are cytotoxic and display Th1-like cytokine secretion profile: Heterogeneity in cytotoxic activity and cytokine secretion levels, Eur. J. Immunol. 23 (1993) 2189-2195.
12. Kumararatne D.S., Pithie A.S., Drysdale P., Gaston J.S.H., Kiessling R., Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis, Clin. Exp. Immunol. 80 (1990) 314-323.
13. Turner J., Dockrell H.M., Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8 T cells in vitro, Immunology 87 (1996) 339-342.
14. DeLibero G., Flesch I., Kaufmann S.H.E., Mycobacteria-reactive Lyt-2 + T cell lines, Eur. J. Immunol. 18 (1988) 59-66.
15. Müller I., Cobbold S.P., Waldmann H., Kaufmann S.H.E., Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4 + and Lyt-2 + T cells, Infect. Immun. 55 (1987) 2037-2041.
16. Canaday D.H., Ziebold C, Noss E.H., Chervenak K.A., Harding C.V., Boom W.H., Activation of human CD8 βTCR cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway, J. Immunol. 162 (1999) 372-379.
17. Lalvani A., Brookes R., Wilkinson R.J., Malin A.S., Pathan A.A., Andersen P., Dockrell H., Pasvol G., Hill A.V., Human cytolytic and interferon gamma-secreting CD8 T lymphocytes specific for Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. USA 95 (1998) 270-275.
18. Stenger S., Mazzaccaro R.J., Uyemura K., Cho S., Barnes P.F., Rosat J.P., Sette A., Brenner M.B., Porcelli S.A., Bloom B.R., Modlin R.L., Differential effects of cytolytic T cell subsets on intracellular infection, Science 276 (1997) 1684-1687.
19. Lewinsohn D.M., Alderson M.R., Briden A.L., Riddell S.R., Reed S.G., Grabstein K.H., Characterization of human CD8 T cells reactive with Mycobacterium tuberculosis - Infected antigen-presenting cells, J. Exp. Med. 187 (1998) 1633-1640.
20. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R., Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection, Proc. Natl. Acad. Sci. USA 89 (1992) 12013-12017.
21. Kaufmann S.H.E., γ/δ and other unconventional T lymphocytes: What do theey see and what do they do?, Proc. Natl. Acad. Sci. USA 93 (1996) 2272-2279.
22. Calmette A., Guérin C., Nègre L., Boquet A., Sur la vaccination préventive des enfants nouveau-nés contre latuberculose par le BCG, Ann. Inst. Pasteur 3 (1927) 201.
23. Huebner R.E., BCG vaccination in the control of tuberculosis, in: Shinnick T.M. (Ed.), Current Topics in Microbiology and Immunology: Tuberculosis, Springer, Berlin, 1996, pp. 263-279.
24. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., Mosteller F., Efficacy of BCG vaccine in the prevention of tuberculosis, JAMA 271 (1994) 698-702.
25. Maharais G.G., Sabo P.J., Mickey M.J., Singh D.C., Stover C.K., Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis, J. Bacteriol. 178 (1996) 1274-1282.
26. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., Small P.M., Comparative genomics of BCG vaccine by whole-genome DNA microarray, Science 284 (1999) 1520-1523.
27. Ladel C.H., Daugelat S., Kaufmann S.H.E., Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: Contribution of CD4 and CD8 T cells to acquired resistance, Eur. J. Immunol. 25 (1995) 377-384.
28. Hess J., Kaufmann S.H.E., Vaccination strategies against intracellular microbes, FEMS Microbiol. Immunol. 7 (1993) 95-103.
29. Cole S.T. et al., Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature 393 (1998) 537-544.
30. Jungblut P.R., Schaible U.E., Mollenkopf H.J., Zimny-Arndt U., Raupach B., Mattow J., Halada P., Lamer S., Hagens K., Kaufmann S.H.E., The comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: Towards functional genomics of microbial pathogens, Mol. Microbiol. 33 (1999) 1103-1117.
31. Harth G., Lee B.Y., Horwitz M.A., High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets, Infect. Immun. 65 (1997) 2321-2328.
32. Alito A., Morcillo N., Scipioni S., Dolmann A., Romano M.I., Cataldi A., VanSoolingen D., The IS6110 restriction fragment length polymorphism in particular multi-drug resistant Mycobacterium tuberculosis strains may evolve too fast for reliable use in outbreak investigation, J. Clin. Microbiol. 37 (1999) 788-791.
33. Ewald P.W., The need for new vaccines, in: Kaufmann S.H.E. (Ed.), Walter de Gruyter, Concepts in Vaccine Development, 1996, pp. 1-70.
34. Riley L.W., Determinants of cell entry and intracellular survival of Mycobacterium tuberculosis, Trends Microbiol. 3 (1995) 27-31.
35. Horwitz M.A., Lee B.W.E., Dillon B.J., Harth G., Protective immunity against tuberculosis induced by vaccination with major extracellular proteins against Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. USA 92 (1995) 1530-1534.
36. Baldwin S.L., D' Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., Ulmer J.B., Huygen K., McMurray D., Orme I.M., Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis, Infect. Immunol. 66 (1998) 2951-2959.
37. Venkataprasad N., Coombes A.G.A., Singh M., Rohde M., Wilkinson K., Hudecz F., Davis S.S., Vordermeier H.M., Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers, Vaccine 17 (1999) 1814-1819.
38. Tascon R.E., Colston M.J., Ragno S., Vaccination against tuberculosis by DNA injection, Nat. Med. 2 (1996) 888-892.
39. Huygen K., Content J., Denis O., Montgomery D.L., Yawman M., Deck R.R., DeWitt C.M., Orme I.M., Baldwin C., D'Souza C, Drowart A., Lozes E., Vandenbussche P., Van Vooren J.P., Liu M.A., Ulmer J.B., Immunogenicity and protective efficacy of tuberculosis DNA vaccine, Nat. Med. 2 (1996) 893-898.
40. Tanghe A., Lefèvre P., Denis P., D'Souza S., Braibant M., Lozes E., Singh M., Montgomery D., Content J., Huygen K., Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors, J. Immunol. 162 (1999) 1113-1119.
41. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., Britton W.J., Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis, Infect. Immunol. (1999) 1702-1707.
42. Denis O., Tanghe A., Palfliet K., Jurion F., Van DenBerg T.P., Vanonckelen A., Ooms J., Saman E., Ulmer J.B., Content J., Huygen K., Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4 and CD8 T-cell epitopic repertoire broader than that stimulates by Mycobacterium tuberculosis H37Rv infection, Infect. Immunol. 66 (1998) 1527-1533.
43. Pelicic V., Jackson M., Reyrat J.M., Jacobs W.R.J.R., Gicquel B., Guilhot C., Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. USA 94 (1997) 10955-10960.
44. Berthet F.X., Lagranderie M., Gounon P., Laurent-Winter C., Ensergueix D., Chavarot P., Thouron F., Maranghi E., Pelicic V., Portnoi D., Marchal G., Gicquel B., Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene, Science 282 (1998) 759-762.
45. Yuan Y., Crane D.D., Simpson R.M., Zhu Y.Q., Hickey M.J., Sherman D.R., Barry C.E., 3rd, The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages, Proc. Natl. Acad. Sci. USA 95 (1998) 9578-9583.
46. Guleria I., Teitelbaum R., McAdam R.A., Kalpana G., Jacobs W.R.J.R., Bloom B.R., Auxotrophic vaccines for tuberculosis, Nat. Med. 2 (1996) 334-337.
47. Murray P.J., Aldovini A., Young R.A., Manipulation and potentiation of anti-mycobacterial immunity using recombinant BCG secreting cytokines, Proc. Natl. Acad. Sci. USA 93 (1996) 934-939.
48. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., Kaufmann S.H.E., Mycobacterium bovis bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes, Proc. Natl. Acad. Sci. USA 95 (1998) 5299-5304.
49. Zhu X., Venkataprasad N., Ivanyi J., Vordermeier H.M., Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis, Immunology 92 (1997) 6-9.
50. Hess J., Kaufmann S.H.E., Live antigen carriers as tools for improved anti-tuberculosis vaccines, FEMS Immunol. Med. Microbiol. 23 (1999) 165-17.